key: cord-0837460-haunewi2
authors: Totomoch-Serra, Armando; Domínguez-Cruz, Miriam Givisay; Manterola, C.; de Lourdes Muñoz, María
title: Variants in AGTR2 gene in Maya people with COVID-19
date: 2021-06-24
journal: Gene
DOI: 10.1016/j.gene.2021.145794
sha: fe6453ba9d262848952bfc8abc4c7e5a5a63bc72
doc_id: 837460
cord_uid: haunewi2

nan

In February 2020, the first cases of COVID-19 were declared in Mexico, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The statistics increased dramatically as the months wore on, accumulating close to 223,072 deaths (May 2021), bringing the country to the fourth lethality position in the world in early 2021 (https://covid19.sinave.gob.mx/). So far, the various environmental causes that lead that point are debatable; however, it is important to consider that genetic causes and high risk for patients with pre-existing comorbidities such as obesity, diabetes, and hypertension, which were already important causes of death in Mexicans, also have an effect on this disease. Concerning these various issues, in 2018, a pilot study was performed in Mexico with the aim of identifying genetic variants that affected type 2 diabetes in people with Maya ethnicity from Yucatan (Dominguez-Cruz et al, 2018) . The results obtained showed the variant rs1914711 located in AGTR2 gene (OR = 6.824; p = 1.448 × 10−9), locus Xq22-q23 (MIM *300034) significantly associated with T2D. Despite the limited sample of the study, it was not found a stratification in the population. This gene encodes the angiotensin II receptor type 2, an interactive part of the protective renin-angiotensin system (RAS; Steckelings and Sumners, 2020) promoting vasorelaxation and participates in the regulation of glucose levels (Geng et al, 2013) . The AGTR2 gene also, has been found to be dominant, highly expressed, and highly specific in humans lungs (2.52 [Magic index = log2(1000 sFPKM]; Cui et al., 2020) , and in the lungs of the 19, but they did not receive ventilator management (Steckelings and Sumners, 2020) . Recently, preliminary results have been published mentioning a 40% reduction in the need for oxygen supplementation in the group that received C21 compound (Tornling et al, 2021) . Previously, the same compound was tested in-vitro, preventing endothelial inflammation and leukocyte adhesion (Rathinasabapathy et al, 2018) and an attenuation in the progression of pulmonary fibrosis and hypertension (Sampson et al, 2016) in in-vitro and in-vivo models.

Given these observations, we suggest that the identification of the high-frequency variant rs1914711 in the AGTR2 gene associated with T2D in a Mayan population, in addition to being a factor for the appearance of T2D, increases the risk of severe Covid-19 disease. In addition, the high mortality in the Maya populations in Yucatan due to COVID-19, also suggests the possibility of using a new therapy with the AGTR2 agonist as a coadjutant. It is essential to point out the need to support and conduct studies in Mexican populations with COVID-19 virus infection, highlighting the need for genomics approaches to increase pharmacogenetics and pharmacogenomics knowledge to advance in the fields of precision medicine in the context of the COVID-19 Pandemic.

AGTR2, one possible novel key gene for the entry of SARS-CoV-2 into human cells

Angiotensin-converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients

Pilot genome-wide association study identifying novel risk loci for type 2 diabetes in a Maya population

Angiotensin-converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients

The Selective Angiotensin II Type 2 Receptor

Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury

Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo

Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists

The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 -a double-blind, randomized, placebocontrolled Phase 2 trial

Safety and efficacy of C21 in subjects with COVID-19

An AGTR2 agonist is under study to fight against lethality in COVID-19 infection